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Background: The mechanisms of smoking tobacco leading to chronic obstructive pulmonary disease (COPD)
are beginning to be understood. However, conclusions about the role of blood or lung oxidative stress
markers were disparate.
Aims: To investigate the oxidative stress in blood or lung associated with tobacco smoke and to evaluate its
effect on pulmonary function data and its relation with physical activity.
Methods: It is a case-control study. Fifty-four male-smokers of more than five pack-years (PY) and aged
4060 years were included (29 Non-COPD, 16 COPD). Physical activity score was determined. Blood sample
levels of malondialdehyde (MDA), protein-cys-SH (PSH), and Glutathione (GSH) were measured. Fractional
exhaled nitric oxide (FeNO) and plethysmographic measurements were performed. Correlation coefficients (r)
evaluated the association between oxidative stress markers and independent variables (plethysmographic data
and physical activity score).
Results: Non-COPD (4896 years) and COPD (4995 years) groups had similar tobacco consumption
patterns, that is, 27914 PY versus 30919 PY, respectively. Compared to the Non-COPD group, the COPD
group had significantly lower levels of GSH and PSH, that is, mean9SE were 4096 versus 2595 mg/mL and
54910 versus 2695 mg/g of hemoglobin, respectively. However, MDA level and FeNO values were similar. In
the COPD group, none of the oxidative stress markers was significantly correlated with plethysmographic
data or physical activity score. In the Non-COPD group, GSH was significantly correlated with physical
activity score (r0.47) and PSH was significantly correlated with total lung capacity (TLC) (r0.50),
residual volume (r0.41), and physical activity score (r0.62). FeNO was significantly correlated with TLC
of the COPD group (r0.48).
Conclusion: Compared to the Non-COPD group, the COPD group had a marked decrease in blood
antioxidant markers (GSH and PSH) but similar blood oxidant (MDA) or lung (FeNO) burden.
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C
hronic obstructive pulmonary disease (COPD)
continues to cause heavy health and economic
burden around the world (1) and in North Africa,
in particular (2). This disease defines a group of chronic
inflammatory pulmonary disorders characterized by air-
flow limitation that is not fully reversible (3, 4). It is
accompanied by systemic manifestations causing serious
impact on the quality of life and survival of patients,
including dyspnea, nutritional depletion, and skeletal
muscle dysfunction, which contribute to exercise intoler-
ance (5). The clinical and functional manifestations of
COPD result from lung injury occurring through various
mechanisms, including chronic inflammation, oxidative
stress, protease/antiprotease imbalance, and apoptosis (6).
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Chronic inflammation is usually the result of tobacco
smoke (8090% of cases); other factors, particularly
occupational exposures, may play a role (3). Oxidative
stress is central in the pathogenesis of COPD, because
smoking is associated with increased oxidative stress in
the lungs (7, 8).
The term ‘oxidative stress’ describes the consequences
of an imbalance between oxidantantioxidant balance,
with the outcome being favorable to oxidants (7). The
highly free radicals mostly represent oxidants. The last can
be centered on oxygen (reactive oxygen species (ROS),
such as malondialdehyde (MDA)) or nitrogen (nitrogen
reactive species (NRS), such as nitric-oxide (NO)). MDA
and NO are toxic products associated with lipid peroxida-
tion and react with protein and deoxyribonucleic-acid
(9, 10). Biological systems are exposed to pollution,
cigarette smoke and generate (production by phagocytes
and mitochondria) continuously oxidizing (10). To oppose
their potential deleterious effects, living organisms, and
lung in particular, have developed a sophisticated antiox-
idant system comprising several molecules, especially gluta-
thione (GSH) and protein-cys-SH (PSH) (68, 11, 12).
GSH is one of the most effective enzymatic antioxidant and
its activity appears to be an important feature in determin-
ing oxidative damage (9, 13). PSH possesses antioxidant
properties which play an important role in protecting
biological systems against the oxidative stress (14).
In practice, oxidative stress can be assessed and moni-
tored through the determination of the levels of biomar-
kers in different biological samples, especially serum and
exhaled-breath-condensate (EBC) (9). In a recent study
(15) aiming to evaluate the difference in the burden of
oxidative stress in patients with COPD, smokers, and
non-smokers by measuring oxidative stress markers in the
EBC samples, authors found significantly higher levels
of 8-isoprostane and H2O2 in the COPD and smokers
groups than in the non-smokers group. However, levels
were similar between smokers and COPD subjects (15).
In addition, MDA levels were similar between the three
groups and there was no correlation between oxidative
stress markers levels and pulmonary function data (15).
The authors concluded that even if respiratory function
tests are within normal limits, oxidant burden in smokers’
lungs is equivalent to that in COPD patients (15). What
about oxidative stress in smokers and COPD blood?
Previous studies have demonstrated that smokers have
higher levels of oxidative stress biomarkers compared to
healthy non-smokers (16, 17). In COPD patients, data are
controversial: higher levels of MDA and lower levels of
PSH and GSH (1820), higher level of GSH in COPD
patients when compared with either healthy non-smokers
or smokers free from COPD (21, 22). Some plausible
explanations of the oxidative stress results discordance
could be subjects’ different physical activity status (23, 24)
or socioeconomic levels (SELs) (25, 26).
The present study aims to investigate the blood and
lung oxidative stress markers of smokers free from
COPD (Non-COPD) and with COPD, and to evaluate its




The present case-control study was performed over an
8-month period (April to November 2013) in Farhat
HACHED Hospital (Sousse, Tunisia). The city lies on
the Gulf of Hammamet on the Mediterranean Sea and
has 173,047 inhabitants (year 2010). In a recent local
population-based prevalence survey (2), a history of cur-
rent or past smoking was found in 47.4 and 74.3% of men.
In addition, 7.8% of the residents aged 40 years or over
had COPD, and this was more common in males than in
females (2).
The study was conducted in accordance with the
Declaration of Helsinki. Participants provided written
consent and the study protocol was approved by the ethics
committee of the hospital (approval number 2204/2013).
Sample size
The null hypothesis (27) was H0: m1m2 and the alter-
native hypothesis was Ha: m1m2d, where d is the
difference between two means and n1 and n2 are the
sample sizes for the Non-COPD and COPD smokers
groups, such Nn1n2. The total sample size was esti-
mated using the following formula (27): N[(r1)
(Za/2Z1-b)
2 s2]/r d2. Za is the normal deviate at a level
of significance of 1.96 (5% level of significance), Z1-b is the
normal deviate at 1-b% power with b% of type II error
(0.67 at 75% statistical power); ‘r’ equal to n1/n2 is the ratio
of sample size required for two groups (r0.5 gives the
sample size distribution as 1:2 for two groups). ‘r’
was considered because of the unequal sample sizes for
various reasons, such as higher prevalence of smokers free
from COPD compared to smokers with COPD (among
661 higher smokers more than 20 pack-years (PY, i.e., one
PYequals one pack a day for 1 year), only 16% had COPD
(2)). s and d are the pooled standard deviation (SD) and
difference of MDA in EBC means of two groups of
smokers (Non-COPD and COPD). These two values
were obtained from a previous study based on a similar
hypothesis (15) in which the researchers found that the
mean MDA (mmol/l) in two groups of smokers (COPD
versus Non-COPD) were 0.08 and 0.07 and common SD
was 0.015. The total sample size for the study was 45
smokers (29 Non-COPD and 16 COPD).
Population
COPD patients were recruited from the pulmonary
department of the local hospital. Non-COPD smokers
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were selected by convenience sampling from the staff of
the local faculty of medicine or hospital, as well as from
acquaintances of people involved in the study.
Only male smokers aged 4060 years without a history
of atopy and free from asthma, allergies, pulmonary
tuberculosis, or recent respiratory tract infection were
included. Imperfect performance of the respiratory maneu-
vers was applied as an exclusion criterion. Only smokers
of more than 5 PY were included. The smoker must
have stopped smoking for at least 6 h (15, 28) and was
asked to fast (no eating or drinking) for at least 10 h
before coming to the hospital. Subjects were asked to
not participate in strenuous activity for 1 h prior to the
fractional exhaled nitric oxide (FeNO) measurements (29).
Smokers presenting an acute response in the first-
second-forced-expiratory-volume (FEV1) and/or forced
vital capacity (FVC) to inhaled bronchodilator of more
than 20% of initial values were excluded. Smokers
were divided into two groups, taking into account the
post-bronchodilator FEV1/FVC ratio. Smokers with a
post-bronchodilator FEV1/FVC ratio 0.70 were con-
sidered as free from COPD and qualified as smokers
Non-COPD group (Non-COPD) (3, 4). Those with a
post-bronchodilator FEV1/FVC ratio 50.70 were con-
sidered as smokers COPD patient group (3, 4).
Subjects with COPD were clinically stable, with no
worsening of symptoms, need of increase in medication,
emergency care, or hospitalization within the previous
4 weeks. Duration of the COPD and medical treatments
were recorded. COPD subjects treated with inhaled corti-
costeroids (budesonide 200400 mg/d, fluticasone 500
1,000 mg/d), inhaled b-adrenergic agonists, theophylline
oral or inhaled N-acetylcysteine or vitamin C and/or E
were excluded.
Collected data
Smokers were evaluated for 1 day. The study protocol was
in the following order: fasting blood sample (MDA, PSH,
and GSH levels); response to medical questionnaire (30)
(schooling level (SL) and SEL, cigarette consumption,
sputum, cough, dyspnea, chest pain, whistling, medical
and surgical histories, and medication use) and physical
activity questionnaire (31) (household, sporting, leisure,
and physical activity scores); and anthropometric data
measurement (age, weight, height, body mass index (BMI));
FeNO assessment and plethysmographic data measure-
ment (FVC, FEV1, FEV1/FVC, mid maximal expiratory
flow (MMEF), slow vital capacity (SVC), thoracic gas
volume (TGV), residual volume (RV), and total lung
capacity (TLC)).
Clinical, SL, SEL, tobacco use, and sports activity
evaluations
Two groups (Yes/No) of smokers were defined according
the presence or the lack of cough, sputum-production,
dyspnea, chest pain, and whistling (30).
Two SLs were defined (32): low (illiterate, primary edu-
cation); and high (secondary and university education).
Two SELs were defined (32): unfavorable (unskilled
worker, jobless); and favorable (skilled worker, farm
owner, manager).
Active smoking was assessed by a series of questions
about past and current consumption. Cigarette use was
evaluated in PY.
A translated version of the Voorrips et al. (31) physical
activity questionnaire was filled out by each smoker, and
household, sporting, and leisure activities were evaluated
to yield a total physical activity score (31). It is a validated
physical activity questionnaire for young and elderly
apparently healthy people (31). The questionnaire pro-
vides a reliable and valid method for classifying subjects
into categories of high, medium, and low physical activity
(31). According to the total physical activity score, two
groups were defined (non-active (scoreB9.4); and active
(score]9.4)).
Physical examination
Anthropometric data were verified, measured, or calcu-
lated: age (year), height (m), weight (kg), BMI (kg/m2).
Height (90.01 m) was measured with a height gauge
(standing stadiometer type DETECTO†) with shoes
removed, heels joined, and back straight. Weight (91 kg)
was measured with a digital scale (OHAUS, Florhman
Park, NJ, USA), and BMI (weight/height2) was calcu-
lated. Depending on BMI, the smokers were classified
as non-obese (BMIB30) and obese (BMI]30) (33).
Blood sample
Venous blood was collected into dry and heparin tubes.
Blood samples were immediately centrifuged at 3,000 rpm
for 10 min, divided into plasma, serum, and red blood
cells, and then stored at 808C. MDA level was esti-
mated based on the method using thiobarbituric acid
(34). Two colors (redpink) were quantified by spectro-
photometer at 535 nm (SPEROL 1,500, Analytic Jena).
PSH level was determined by subtracting the non-protein
thiols from total thiols (35). GSH level was determined
based on the color complex formation of non-protein
sulfydryl groups, which were separated by deproteiniza-
tion with trichloroacetic acid (35). High level of MDA
and low levels of GSH and PSH are signs of a significant
oxidative stress (36).
FeNO measurement
The FeNO (ppb) was measured by Medisoft HypAir FeNO
method using an electrochemical analyzer (Medisoft,
Sorinnes (Dinant), Belgium). International recommenda-
tions were respected (37). The instrument was calibrated
and used according to the manufacturer’s instructions
and worked in conjunction with a personal computer.
The software supplied by the manufacturer provided
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both audio and visual feedback allowing the participant
to maintain a constant exhaled breath flow rate (37).
The online method, with constant flow rate was used
(37). After a full unforced exhalation outside the mouth-
piece, a maximal inspiration was performed through an
absorber to ensure NO-free air. The subject then per-
formed a controlled exhalation using flow control at an
exhalation pressure of 410 cmH2O for at least 10 sec,
during which time sample collection and gas analysis was
performed. Nasal contamination is presented by closure
of the velum by using five cmH2O oral back-pressures.
A nose clip was not used. The subjects maintained the
required flow rate of 50 mL/sec with the aid of visual
feedback from the computer screen. Three acceptable
measurements were taken within a 15-min period (37).
The mean of the three values was used (37).
Lung function measurements and applied definition
The spirometric measurements were performed with a body
plethysmograph (ZAN 500 Body II Mebgreräte GmbH,
Germany), carefully following international recommen-
dations (38, 39).
The plethysmographic technique followed these steps: 1)
the procedure was explained to smokers in detail; 2) the
plethysmograph door was closed and time was allotted
for thermal transients to stabilize, and patients to relax;
3) smokers were instructed to attach the mouthpiece and
breathe quietly until they achieved stable end-expiration,
4) when smokers were at or near TGV, the shutter was
closed at end-expiration for 23 sec, and they were in-
structed to perform a series of gentle pants at a frequency
of 0.51.0 Hz; 5) after a series of 35 technically satis-
factory pants, maneuvers were recorded; 6) the shutter
opened and patients performed an expiratory reserve
volume maneuver followed by a SVC maneuver; 7) with
regards to repeatability, at least three TGV values that
agreed within 5% were obtained and the mean value
reported.
The FVC maneuver had three distinct phases: maximal
inspiration, a blast of exhalation, and continued complete
exhalation to the end of testing. Smokers were verbally
encouraged to continue exhaling air at the end of the
maneuver to obtain optimal effort. The criterion for end
of testing was a volumetime curve showing no change
in volume (25 mL) for 1 sec, despite the patient’s effort
to exhale for at least 6 sec. Repeatability was accep-
table when the difference between the largest and the
next largest FVC was B150 mL, and the difference
between the largest and next largest FEV1 was B150 mL.
Plethysmographic parameters were measured or calcu-
lated before/post-bronchodilator inhalation of 400 mg
Salbutamol† via a large volume spacer (40) and com-
pared with local predicted values (41).
Lung hyperinflation was defined as an abnormal
increase in RV higher than the upper limit of normal
(42). COPD diagnosis was retained when the post-
bronchodilator FEV1/FVC ratio was lower than 0.70 (3, 4).
Statistical analysis
Variables distributions were normal.
Smokers’ characteristics and lung function data of the
two groups were expressed as mean9SD and/or 95%
confidence interval (95% CI).
Biological markers were expressed as mean9standard
error (SE) and 95% CI.
Student t-test was used to compare means of quanti-
tative data (physical scores, anthropometric, lung func-
tion data, and oxidative stress markers), and chi-square
test was used to compare qualitative data (obesity and
socioeconomic status, clinical and pathological data).
Pearson productmoment correlation coefficients (r)
evaluated the associations between oxidative stress mar-
kers and independent variables such as lung function data
expressed as percentage of predicted values (FEV1, TLC,
and RV), FeNO, and physical activity score. In addition,
correlation coefficients were used to evaluate the associa-
tions between FeNO and the above lung function data and
physical activity score.
All mathematical computations and statistical proce-
dures were performed using Statistica statistical software
(Statistica Kernel version 6; Stat Software. France).
Significance was set at the 0.05 level.
Results
Characteristics of the two groups
Table 1 presents the characteristics of the two groups.
There were no statistically significant differences be-
tween their ages or the amounts of tobacco they used.
Compared to Non-COPD group, the COPD one had
significantly:
1. Lower height, weight, and BMI. However, the two
groups contain statistically similar percentages of
obese smokers.
2. Lower percentage of subjects having a high SL.
3. Lower household, sporting, leisure, and physical
activity scores.
4. Higher percentages of ‘sputum-producers’ and dys-
pnea smokers.
FeNO and plethysmographic data
Table 2 presents the FeNO and the plethysmographic data
of the two groups. Compared to Non-COPD group, the
COPD group had significantly lower FEV1 (L,%), FVC
(L), FEV1/FVC ratio (absolute value), MMEF (L,%),
and SVC (L). However, no significant difference was
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found between the two groups’ static volumes (TLC, RV,
or TGV) or FeNO data.
The percentage of smokers with lung-hyperinflation
was similar between the COPD and the Non-COPD
groups, 4 (25%) versus 4 (14%), respectively, p0.36.
Table 3 presents the correlations between FeNO and
lung function data and physical activity score in the two
groups. FeNO was significantly correlated only with TLC
of the COPD group.
Oxidative stress markers levels
Figure 1 presents the levels of oxidative stress markers in
the two groups. Compared to the Non-COPD group, the
COPD group had significantly lower levels of GSH and
PSH, mean9SE, were 40.4695.56 versus 24.6795.41
mg/mL and 53.59910.44 versus 25.7295.03 mg/g of hemo-
globin, respectively. However, MDA level was similar
for the two groups, means9SE were 15.7990.94 versus
12.7391.49 mmol/L, respectively.
Table 1. Clinical characteristics of the two groups: smokers’ Non-COPD and COPD
Non-COPD (n29) COPD (n16)
Anthropometric, physical activity, and tobacco use data (Data are mean9SD [95%CI])
Age (years) 47.9395.66 [45.7750.8] 48.9995.33 [46.1551.83]
Height (m) 1.7390.07 [1.701.75] 1.6790.06 [1.631.70]a
Weight (kg) 83917 [7790] 68914 [6078]a
Body mass index (kg/m2) 27.9394.95 [26.0429.82] 24.5795.24 [21.7727.36]a
Household activity score 1.3690.53 [1.161.56] 0.8890.31 [0.711.05]a
Sporting activity score 4.4294.84 [2.576.26] 0.3390.54 [0.040.62]a
Leisure activity score 2.5391.63 [1.923.15] 1.6490.58 [1.341.95]a
Physical activity score 8.3194.86 [6.4610.16] 2.8690.78 [2.443.27]a
Cigarettes use (PY) 27914 [2233] 30919 [2041]
Obesity, socioeconomic status, clinical, and pathological data (data are number (percentage))
Obesity status Obese 10 (34.5) 2 (12.5)
Non-obese 19 (65.5) 14 (87.5)
Schooling level High 20 (68.9) 6 (37.5)b
Low 9 (31.0) 10 (62.5)b
Socioeconomic level Favorable 13 (44.8) 5 (31.2)
Unfavorable 16 (55.2) 11 (68.7)
Cough Yes 11 (37.9) 45 (25.0)
No 18 (62.1) 12 (75.0)
Sputum Yes 10 (34.5) 6 (37.5)
No 19 (19.5) 10 (62.5)b
Dyspnea Yes 12 (12.4) 8 (50.0)b
No 17 (58.6) 8 (50.0)
Chest pain Yes 6 (20.7) 2 (12.5)
No 23 (79.3) 14 (87.5)
Whistling Yes 3 (10.3) 1 (06.2)
No 26 (89.7) 15 (93.7)
Recent respiratory infection Yes 0 (0.0) 2 (12.5)
No 29 (100) 14 (87.5)
Emphysema Yes 0 (0.0) 0 (0.0)
No 29 (100) 16 (100)
Diabetes Yes 0 (0.0) 0 (0.0)
No 29 (100) 16 (100)
High blood pressure Yes 2 (6.90) 3 (18.5)
No 27 (93.1) 13 (81.2)
Cardiovascular diseases Yes 0 (0.0) 0 (0.0)
No 29 (100) 16 (100)
Surgical history Yes 3 (10.3) 0 (0.0)
No 26 (89.7) 16 (100)
apB0.05 (t-test): Non-COPD versus COPD. bpB0.05 (chi-square test): Non-COPD versus COPD.
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Table 4 presents the levels of oxidative stress markers
in the two groups divided according to the obesity status.
Comparison of the non-obese versus obese smokers for
the same smokers group revealed a significant statistical
difference only for the GSH of the COPD group (it was
significantly higher in the obese subgroup compared to
the non-obese group). Comparison of the Non-COPD
versus COPD smokers for the same obesity status re-
vealed that the COPD obese subgroup has a significantly
lower MDA level when compared to the Non-COPD obese
subgroup. In addition, the COPD non-obese subgroup
has significantly lower levels of PSH and GSH when
compared with the Non-COPD non-obese subgroup.
Table 5 presents the correlations between oxidative
stress markers and lung function data and physical activity
score in the two groups. In the COPD group, none of the
oxidative stress markers was significantly correlated with
lung function data or physical activity score. However,
in the Non-COPD group, GSH was significantly cor-
related with physical activity score (r0.47), and PSH
was significantly correlated with TLC, RV, and phy-
sical activity score (respectively, r0.50, r0.41 and
r0.62).
Discussion
We compared two age- and amount of tobacco used-
matched groups of smokers of more than 5 PY: 29 Non-
COPD and 16 COPD. Compared to the Non-COPD
group, the COPD group had significantly lower levels of
GSH and PSH. However, MDA level and FeNO values
were similar for the two groups. Therefore, the null hypo-
thesis, that there is no difference between the MDA levels
of the two groups is retained. In the COPD group, none of
the oxidative stress markers was significantly correlated
with lung function data or physical activity score. How-
ever, in the Non-COPD group, GSH was significantly
correlated with physical activity score and PSH was sig-
nificantly correlated with TLC, RV, and physical activity
score. FeNO was significantly correlated only with TLC
of the COPD group.
Study limitations
Convenience sampling is a statistical method of drawing
representative data by selecting people because of the
ease of their volunteering (43). Its advantages are the
Table 2. Fractional exhaled nitric oxide (FeNO) and plethysmographic data of the two groups: smokers’ Non-COPD and COPD
Non-COPD (n29) COPD (n16)
First-second-forced-expiratory-volume (FEV1) L 3.1190.47 [2.933.29] 2.0590.67 [1.692.41]
a
% 88910 [8492] 62918 [5372]a
Forced vital capacity (FVC) L 4.1490.62 [3.904.37] 3.4790.90 [3.003.95]a
% 95911 [9199] 87918 [7796]
FEV1/FVC (absolute value) 0.7590.043.91 [0.740.77] 0.5890.08 [0.540.63]
a
Mid maximal expiratory flow L 2.5690.65 [2.312.80] 1.0290.46 [0.781.26]a
% 64915 [5870] 26911 [2132]a
Slow vital capacity L 4.0990.63 [3.854.33] 3.4690.86 [3.013.92]a
% 90912 [8695] 83916 [7592]
Total lung capacity L 5.8691.25 [5.386.33] 5.7190.96 [5.206.22]
% 87916 [8193] 92914 [8499]
Residual volume L 1.9491.23 [1.472.41] 2.1490.73 [1.752.53]
% 92956 [71113] 106938 [86126]
Thoracic gas volume L 3.7191.52 [3.134.28] 3.7890.91 [3.304.26]
% 109943 [93125] 117929 [101132]
FeNO ppb 13.8397.11 [11.1216.53] 14.8896.95 [11.1718.58]
Plethysmographic data are measured before use of bronchodilator and expressed in absolute values and as percentage of predicted
values. Data are mean9SD [95% confidence interval]. apB0.05 (t-test): Non-COPD versus COPD.
Table 3. Correlation coefficient between fractional exhaled
nitric oxide (FeNO) and lung function data and physical
activity score in the two groups: smokers’ Non-COPD
(n29) and COPD (n16)
FeNO (ppb)
First-second-forced- Non-COPD 0.04
expiratory-volume (%) COPD 0.14
Total lung capacity (%) Non-COPD 0.06
COPD 0.48a
Residual volume (%) Non-COPD 0.01
COPD 0.44
Physical activity score Non-COPD 0.12
COPD 0.12
Plethysmographic data were measured before bronchodilator
use and were expressed as percentages of references values.
apB0.05 (Pearson product-moment correlation coefficient).
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availability and the quickness with which data can be
gathered (43). Its disadvantages are the risk that the
sample might not represent the population as a whole,
and it might be biased by volunteers (43).
In the present study, we have compared oxidative stress
levels of Non-COPD smokers with these of COPD
smokers. Other authors have compared COPD sub-
jects with both healthy smokers and healthy non-smokers
(15) or have compared smokers’ subjects with both
passive smokers and non-smokers without tobacco
smoke exposure (9). However, taking three groups in a
single study seems to have limited precedence in litera-
ture and raises some substantive questions such as
whether the prevalence of COPD in the three groups is
comparable.
Occupational exposure is a risk factor for COPD (3).
For that reason, socioeconomic evaluation, based on the
job of the smoker, was done and the SELs of the two
Fig. 1. Oxidative stress levels of the two groups: smokers Non-COPD (Non-COPD) and smokers COPD patients (COPD).
a) Malondialdehyde (MDA) level measured in 26 Non-COPD and 15 COPD smokers. b) Glutathione (GSH) level measured
in 24 Non-COPD and 15 COPD smokers. c) Protein sulfhydryl (PSH) level measured in 24 Non-COPD and 16 COPD.
Data are shown as box-and-whisker plots illustrating the mean ( ), 9standard-error ( ), and 95% confidence
interval ( ). p (t-test): comparison of levels of oxidative stress markers between the two groups.
Oxidative stress and lung function in male smokers
Citation: Libyan Journal of Medicine 2014, 9: 23873 - http://dx.doi.org/10.3402/ljm.v9.23873 7
(page number not for citation purpose)
groups was compared (Table 1). There was no significant
difference between the two groups SELs, therefore, we
can speculate that they were controlled (matched) for
occupational exposures.
The present calculated sample size (n45 smokers:
29 Non-COPD and 16 COPD) seems to be satisfactory.
It is closer to that of Inonu et al. (15) (n51 smokers:
26 Non-COPD and 25 COPD) but smaller to that of
Hanta et al. (44) (n101 smokers: 30 Non-COPD and
71 COPD) or to that of Arja et al. (19) (n386 smokers:
150 Non-COPD and 236 COPD).
Cigarette smoke is a complex mixture of chemical
compounds and smoking is associated with increased
oxidative stress in the lungs (9). There are many studies in
literature reporting an increase in lipid peroxidation and
in the release of oxygen radicals, decreased antioxidant
capacity, and an imbalance of oxidant/antioxidant status
in smokers (612, 15).
Oxidative stress can be assessed and monitored
through the determination of the levels of biomarkers
in different biological samples, such as serum, urine,
bronchoalveolar-lavage-fluid, induced sputum, bronchial
biopsy, and EBC (9, 15). In the present study, the choice
was made for blood sample, which is a little bit inva-
sive method, and FeNO. However, it was desirable to add
collection of EBC, suggested as a simple, non-invasive,
and easily repeatable procedure. In addition, samples
from the lower respiratory tract for monitoring airway
inflammation and oxidative stress can be obtained with
this technique (9, 15).
Several oxidative stress markers are measurable in lung
or in blood. In the present study, two oxidative stress
markers were evaluated, one in blood (MDA) and one in
lung (FeNO); and two blood anti-oxidant markers (GSH
and PSH) were measured. Some authors have opted
for other oxidative stress markers such as 8-Isoprostane
and hydrogen peroxide (15) or 8-hydroxydeoxyguanosine,
nitrite/nitrate, vitamin C, superoxide dismutase, and
GSH peroxidase (9).
Correlations between oxidative stress markers and
initial lung function parameters were analyzed. Three
plethysmographic parameters, expressed as percentage of
Table 4. Oxidative stress markers of the two groups (smokers’ Non-COPD and COPD) divided according to the obesity status
Non-COPD (n29) COPD (n16)
Non-obese (n19) Obese (n10) Non-obese (n14) Obese (n2)
Malondialdehyde (mmol/l) 15.7491.22 15.8991.55 13.5091.60 7.7592.42a
Fractional exhaled nitric oxide (ppb) 14.2191.73 13.1092.08 14.2191.92 19.5091.50
Protein sulfhydryl (mg/g of hemoglobin) 58.77913.30 44.95917.46 23.9995.28a 37.80918.18
Glutathione (mg/mL) 45.5098.42 33.4096.07 20.4693.43a 52.00936.00b
Data are mean9SE. Non-obese (body mass index (BMI) B30 kg/m2). Obese (BMI]30 kg/m2). apB0.05 (t-test): Non-COPD versus
COPD for the same obesity status (Non-obese or Obese). bpB0.05 (t-test): Non-obese versus Obese for the same group (Non-COPD or
COPD).
Table 5. Correlation coefficient between oxidative stress markers and lung function data and physical activity score in the two
groups: smokers’ Non-COPD (n29) and COPD (n16)
MDA GSH PSH
First-second-forced-expiratory-volume (%) Non-COPD 0.23 0.03 0.15
COPD 0.02 0.21 0.46
Total lung capacity (%) Non-COPD 0.10 0.17 0.03
COPD 0.08 0.49 0.50a
Residual volume (%) Non-COPD 0.04 0.22 0.41a
COPD 0.12 0.15 0.08
Fractional exhale nitric oxide (ppb) Non-COPD 0.16 0.21 0.14
COPD 0.05 0.36 0.10
Physical activity score Non-COPD 0.14 0.47a 0.62a
COPD 0.10 0.11 0.14
Plethysmographic data were measured before bronchodilator use and were expressed as percentages of references values. MDA:
Malondialdehyde (mmol/l) was determined in 26 Non-COPD and 15 COPD smokers; GSH: Glutathione (mg/mL) was determined in 24
Non-COPD and 15 COPD smokers; PSH: Protein sulfhydryl (mg/g of hemoglobin) was determined in 25 Non-COPD and 16 COPD
smokers. apB0.05 (Pearson productmoment correlation coefficient).
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predicted values were chosen (Table 5): FEV1, TLC, and
RV. FEV1 is a sensitive index for proximal airways, highly
reproducible (38). This index selection is the most widely
used among the indices of forced expiration to study the
variations of lung obstruction after bronchodilator use
(40). TLC and RVare two volumes often used in practice to
evaluate lung hyperinflation, a pattern frequently seen in
smokers (42). Lung hyperinflation, a major functional
consequence of COPD, is well correlated with dyspnea
(45). In addition, correlations between FeNO values and
the above plethysmographic parameters were also evalu-
ated. In a recent study, done on Tunisian healthy non-
smoking adult males, FeNO values were not correlated with
plethysmographic data (29) and to the best of our knowl-
edge, no study has evaluated the correlation between
smokers’ FeNO and lung volumes, such as TLC or RV.
The present study presented three limitations. The
first one was about diurnal variations of some analyzed
markers (15). As stated by Inonu et al. (15) repeated
measurements at different hours of the day could improve
the reliability of the results. As in other studies (9, 15),
repeated measurements were not used in the present one,
but all blood samples were taken at the same time of
day to avoid possible differences due to diurnal changes.
The second limitation was about females’ non-inclusion.
As in other studies (9, 15), the study groups were more
homogeneous in order to exclude changes caused by sex
differences (15). The last limitation was about inclusion
of obese smokers. Obesity induces systemic oxidative
stress in part through increased production of ROS in
adipose tissue (46). It is hypothesized that the lung serves
as a target organ for this oxidative stress (46). This is
manifested as increased oxidation of airway NO into
nitrate and NRS and hence reduction of NO bioavail-
ability and exhaled NO levels (46). In the present study
(Table 4), 12/49 (27%) smokers (10 Non-COPD and
2 COPD) were obese. First, this percentage was similar
to that described in Tunisian general population (47)
(prevalence of obesity in the total population was 28%)
and the present study sample could be a ‘representative
sample’ of Tunisian population. Second, the present
study COPD sample was also representative of COPD
population where obesity prevalence is around 18% (48).
In a recent local study (42), it was found that 13% of the
366 COPD smokers have obesity. Third, the two groups
of Non-COPD and COPD contain statistically similar
percentages of obese smokers. At least, when we have
looked for correlation between oxidative stress markers
and lung function data, the last were expressed as per-
centage predicted values and so adjusted to anthropo-
metric data, especially weight. In addition, Table 4 data
show, paradoxically, that obese smokers have a statisti-
cally higher level of anti-oxidant marker (GSH) when
compared with non-obese smokers.
Oxidative stress markers: FeNO and MDA
NO is one of the major ROS in cigarette smoke (49).
In the present study, FeNO levels were similar in the two
groups. Assessment of FeNO in patients with COPD
provides seemingly conflicting results: it has been reported
to range from low (50) to elevated (51) values when
compared to those of healthy subjects, with several studies
reporting no difference between these groups (5255).
Maziak et al. (56) showed that COPD patients, particu-
larly those with unstable disease, have higher levels of
FeNO than smokers with chronic bronchitis. These results
were supported by Kanazawa et al. (54) who found higher
FeNO levels in COPD patients than in healthy controls.
However, some other authors (52, 53, 55) reported no
differences in FeNO levels between stable COPD patients
and healthy controls. In addition, FeNO was not asso-
ciated with the severity of COPD (57). This variability
may in part be explained by the heterogeneous nature
of the disease, with multiple factors influencing FeNO.
At the alveolar level, NO rapidly combines with reduced
hemoglobin and is therefore scavenged by pulmonary
capillary blood (51). In the presence of an altered
ventilationperfusion mismatch in COPD, this scavenging
will take place less efficiently (51). Destruction of alveolar
epithelial cells in more severe COPD may influence NO
production in the airways, and the development of cor
pulmonale in severe COPD may reduce FeNO, presumably
as a reflection of endothelial injury. Furthermore, smok-
ing (current or former) influences the composition of the
airway inflammation and thus FeNO formation (58).
MDA is the most mutagenic product of lipid per-
oxidation and can be determined in serum, bronchoalveo-
lar lavage fluid, and tissues (10). Lipid peroxidation
describes the oxidation reactions between ROS and poly-
unsaturated fatty acids, it reflects the degradation of lipids
by oxidative stress inducing changes in the structure and
the permeability of lung membrane and causing a loss of
selectivity of ion exchange (44). In the present study, MDA
levels were similar between the two smokers’ groups.
Literature data about MDA in smokers are controversial.
Morrison et al. (59) have shown that lipid peroxidation
products in plasma and bronchoalveolar lavage measured
as thiobarbituric acid reactive substance were higher in
smokers compared to non-smokers. This result was con-
firmed by other authors (9, 60). Hanta et al. (44) showed
that the plasma concentration of MDA was higher in
smokers Non-COPD and COPD patients than in healthy
non-smokers. This result was recently confirmed by Arja
et al. (19) who showed that COPD patients had higher
MDA levels compared to smokers Non-COPD, 3.2390.57
and 1.4690.14 nmol/mL, respectively.
Anti-oxidative stress markers: GSH and PSH
Cigarette smoke affects antioxidant defense of the
lungs (61). GSH is one of the most effective enzymatic
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endogenous antioxidants and its activity appears to be an
important feature in determining oxidative damage (9, 13).
In the present study, compared to the Non-COPD group,
the COPD group had a significantly lower level of GSH.
This result is in agreement with other studies (19, 62, 63)
but in contrast with other studies showing an increase
(21) or no changes (22) in the GSH concentration in
COPD. Other studies have shown that smokers have low
plasma antioxidant defenses (59). Smoking plays a key
role in lung diseases such as COPD, and cigarette smoke
contains millions of oxygen free radicals (64), so it may
be the cause of the decrease in the content of GSH. This
is confirmed by studies showing a reduction of GSH in
plasma after exposure to cigarette smoke (65). Additional
studies are necessary to disclose the exact mechanisms
primarily responsible. The decline in GSH levels may
reflect a decrease in antioxidant capacity of lung tissue
in patients with COPD as the GSH redox cycle is a
fundamental element of the antioxidant defense system
(66). The oxidantantioxidant balance is affected by the
decrease in antioxidant mechanisms. Indeed, deficiencies
in antioxidant enzymatic and non-enzymatic systems
have been described in patients with COPD (67). This
depletion can be explained by the increased oxidants
produced by activated circulating neutrophils in COPD
(68), directly and indirectly through the recruitment and
activation of inflammatory cells by cigarette smoke (69).
Thus, additional studies are needed to investigate the
regulation of GSH levels in the lungs of smokers and
patients with COPD to design therapy antioxidant GSH.
PSH possesses antioxidant properties which play an im-
portant role in protecting biological systems against the
oxidative stress (14). PSH can take part in the protection
of cells against free radicals and at the same time they are
involved in the regulation of cellular homeostasis’ (70).
These proteins appear to be targets for ROS. Their oxi-
dation leads to the formation of disulfide bonds between
SH groups, which decrease their content (71). Compared
to the Non-COPD group, the COPD group had sig-
nificantly lower level of PSH. This result is consistent
with those of other studies (65, 72). Protein damages can
often be more important than those of lipids in oxidative
stress conditions (73). It is well known that oxidative
damage of proteins results in decreased levels of PSH
(74). The decline of PSH is a marker of oxidative stress.
According to Nagler et al. (75) cigarette smoke is the
cause of this PSH depletion.
Correlation between oxidative stress markers
and plethysmographic data or physical
activity score
In the present study, FeNO was negatively and signifi-
cantly correlated only with TLC of the COPD group
(Table 3). Dweik et al. (76) found that TLC increased
linearly with increased air trapping as measured by
elevated ratio of RV to TLC. The independent associa-
tion of elevated FeNO with increased TLC is a novel
finding and suggests that there is an inflammatory com-
ponent affecting lung mechanics that is separate from the
air trapping mechanism in asthma. However, this hypoth-
esis did not explain the present study result in COPD.
Doruk et al. (9) did not detect any correlation between
NO levels and pulmonary function test data and they
hypothesized that their result could be associated with
reversible decrease in NO levels. Indeed, in many studies
it was reported that NO levels decrease in smokers.
This reduction is reversible and NO levels increase after
smoking cessation (9). Cigarette smoke may inhibit NO
production by multiple mechanisms. Cigarette smoking
causes a transient decrease in exhaled NO that returns
to baseline levels within 15 min. This transient effect is
consistent with the known inhibition of NO-synthase
activity by NO which is present in cigarette smoke in
high concentrations (77). However, this transient decrease
would not seem to explain the lower levels of exhaled NO
in cigarette smokers that were observed after abstinence
for at least 8 h. This more sustained reduction would
be more consistent with the reduction of the transcription
of the inducible form of NO-synthase, the family of
enzymes responsible for the NO production.
As in the study of Doruk et al. (9), no correlation
was found between MDA levels and plethysmographic
data (Table 5). It is known that MDA is not the most
powerful marker of pulmonary oxidative stress (9). There
are other different lipid peroxidation products such as
the 8-Isoprostane. The last is the most widely studied
marker of systemic and pulmonary oxidative stress (78),
and as one of the mediators of the reversible component
of obstruction in patients with COPD (79); and lipid
peroxidation was obviously increased in patients with
COPD especially at severe stage of this disease (72).
As found by Doruk et al. (9), no correlation was found
between GSH levels and plethysmographic data (Table 5).
PSH was correlated with TLC of the COPD group and
with the RV of the Non-COPD group (Table 5). The
correlation between PSH and lung volumes can suggest
that oxidative stress and lung hyperinflation are posi-
tively related. Indeed, Garcia-Rio et al. (80) showed that
in stable patients with COPD, dynamic hyperinflation is
related to the level of airway oxidative stress.
Physical activity score was significantly correlated with
the GSH and the PSH levels of the Non-COPD group
(Table 5). In the present study, the Non-COPD group was
more active than the COPD group (Table 1). It has
recently been suggested that regular exercise reduces
lung function decline and risk of COPD among active
smokers; and one plausible mechanism involved in this
effect was decrease in oxidative stress markers and/or
increase of antioxidant markers (24). As other authors
(24), we can hypothesize that regular aerobic physical
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training attenuates the development of pulmonary dis-
ease induced by cigarette smoke exposure.
Future recommendations
In smokers free from COPD, the associations determined
between physical activity score and GSH and/or PSH,
or between PSH and lung volumes suggested that these
biomarkers might be used in early diagnosis of airway
disease. It would be very interesting to investigate the
oxidative stress in the blood associated with tobacco
smoke and to evaluate its effect with a 6-min-walk-test
(81) and its relation with physical activity.
In conclusion, compared to smokers free from COPD,
those with COPD had a marked decrease in the blood
antioxidant markers (GSH and PSH) but similar blood
oxidant (MDA) or lung (FeNO) burden.
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